Previous 10 | Next 10 |
AtriCure (NASDAQ: ATRC ) prices underwritten offering of 3,977,273 common shares at $44.00 per share for gross proceeds of $175M. More news on: AtriCure, Inc., Healthcare stocks news, , Read more ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the pricing of its underwritten offering of 3,977,273 shares of its common stock at a price to the public of $44.00 per share pursuan...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced a proposed underwritten public offering in which it expects to issue and sell approximately $100 million of shares o...
Previously, I wrote how indiscriminate buying would be replaced with selectivity and that the market was approaching an important make-or-break moment following its rapid run-up since March. The S&P 500 remains below critical resistance, so the risk of weakness remains. However, our ...
AtriCure (NASDAQ: ATRC ) announces positive results from the CONVERGE IDE study evaluating its EPi-Sense device in a procedure called hybrid Convergent ablation to treat patients with persistent atrial fibrillation (AF). More news on: AtriCure, Inc., Healthcare stocks news, Stocks on t...
Results presented virtually via Heart Rhythm 365 Platform; study met primary effectiveness endpoint of superiority in favor of the hybrid Convergent procedure AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA)...
Image source: The Motley Fool. AtriCure Inc (NASDAQ: ATRC) Q1 2020 Earnings Call Apr 29, 2020 , 4:30 p.m. ET Operator Continue reading
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will host an analyst and institutional investor update webcast at 1:00 p.m. Eastern Time on Friday, May 8, 2020, to ...
AtriCure, Inc. (ATRC) Q1 2020 Earnings Conference Call April 29, 2020, 16:30 ET Company Participants Lynn Lewis - Gilmartin Group Michael Carrel - CEO, President & Director Andrew Wade - CFO Conference Call Participants Lilia-Celine Breton Lozada - JPMorgan Chase & ...
AtriCure (NASDAQ: ATRC ): Q1 Non-GAAP EPS of -$0.36 beats by $0.04 ; GAAP EPS of -$0.42 misses by $0.01 . More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval from the National Medical Products A...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2024 financial results on Tuesday, Ju...